Basit öğe kaydını göster

dc.contributor.authorKader, Çiğdem
dc.contributor.authorGöçmen, Ayşe Yeşim
dc.contributor.authorDemir, Münire Islak
dc.contributor.authorÇolak, Nuriye Yalçin
dc.contributor.authorGök, Sebnem Eren
dc.contributor.authorArıkan, Fatma İnci
dc.contributor.authorSara, Mehmet Yıldırım
dc.contributor.authorErbay, Ayse
dc.date.accessioned2021-06-03T05:51:23Z
dc.date.available2021-06-03T05:51:23Z
dc.date.issued2019
dc.identifier.issn0256-4947
dc.identifier.urihttp://dx.doi.org/10.5144/0256-4947.2019.37
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464676/
dc.identifier.urihttp://hdl.handle.net/11655/24156
dc.description.abstractBACKGROUND Since routine immunization could change the epidemiological profile of hepatitis A virus (HAV) infection in the future, it is important to determine the baseline immunity to HAV across Turkey. OBJECTIVE The aim of this study was to determine the seroprevalence of hepatitis A among individuals 6 years of age and older in Yozgat, Turkey. DESIGN Cross-sectional. SETTING Community in central region of Turkey. PATIENTS AND METHODS Questionnaires and blood specimens were collected and the presence of hepatitis A IgG antibodies against hepatitis A virus was determined quantitatively by ELISA. MAIN OUTCOME MEASURES The rates of hepatitis A immunity by age group. SAMPLE SIZE 1862. RESULTS Immunity to hepatitis A was 79.1% (n=1473). The mean (SD) age was 17.1 (14.7) years in the nonimmune group and 37.8 (19.5) years in the immune group (P<.001), and immunity increased with age. No significant difference in immunity rate was detected between genders in children and adults. The seropositivity rate for subjects ages 6–19 years was lower than in subjects aged 20–96 years (52.2% versus 93.9%; P<.001). CONCLUSION A catch-up vaccination program is needed for persons aged 6–19 years in Yozgat. LIMITATIONS Single region data which can not be generalized. For this reason, a multi-centered study that can reflect the whole country is recommended.
dc.language.isoen
dc.relation.isversionof10.5144/0256-4947.2019.37
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleHepatitis A Immunity In Yozgat, Turkey
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAnnals Of Saudi Medicine
dc.contributor.departmentTıbbi Farmakoloji
dc.identifier.volume39
dc.identifier.issue1
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States